Cure diseases and help the world's people...or keep lining your pockets while people suffer?

It finally happened: Goldman Sachs asks 'Is curing patients a sustainable business model?'
It isn’t “good business,” to be absolutely frank. We all know it isn’t. There are entire fringe worlds of conspiracy that continue to exist based on this one single kernel of truth. Why is this news now? Because science and medicine are getting very close to big and meaningful breakthroughs on diseases and maladies that were once only somewhat treatable with very expensive routines of medications. Gene therapy breakthroughs have been a big part of this, with the FDA approving promising gene therapy trials, and even more exciting results coming in from around the world. But as CNBC reports, solving serious problems for the public doesn’t mean you get to keep buying mega-yachts. Goldman Sachs analyst Salveen Richter has some bad news for our current “free market” system:


Most of us know that there is a better chance of Santa Claus showing up at our home and flying us to the moon than private industry doing what’s right for the world over what’s right for the bottom line of private industry.

Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'

Drop dead, America: Trump's billion-dollar budget cuts to medical research and disease prevention